Ludwig Institute for Cancer Research, Uppsala University, Uppsala, Sweden.
Physiol Rev. 2012 Oct;92(4):1619-49. doi: 10.1152/physrev.00046.2011.
Stem cell factor (SCF) is a dimeric molecule that exerts its biological functions by binding to and activating the receptor tyrosine kinase c-Kit. Activation of c-Kit leads to its autophosphorylation and initiation of signal transduction. Signaling proteins are recruited to activated c-Kit by certain interaction domains (e.g., SH2 and PTB) that specifically bind to phosphorylated tyrosine residues in the intracellular region of c-Kit. Activation of c-Kit signaling has been found to mediate cell survival, migration, and proliferation depending on the cell type. Signaling from c-Kit is crucial for normal hematopoiesis, pigmentation, fertility, gut movement, and some aspects of the nervous system. Deregulated c-Kit kinase activity has been found in a number of pathological conditions, including cancer and allergy. The observation that gain-of-function mutations in c-Kit can promote tumor formation and progression has stimulated the development of therapeutics agents targeting this receptor, e.g., the clinically used inhibitor imatinib mesylate. Also other clinically used multiselective kinase inhibitors, for instance, sorafenib and sunitinib, have c-Kit included in their range of targets. Furthermore, loss-of-function mutations in c-Kit have been observed and shown to give rise to a condition called piebaldism. This review provides a summary of our current knowledge regarding structural and functional aspects of c-Kit signaling both under normal and pathological conditions, as well as advances in the development of low-molecular-weight molecules inhibiting c-Kit function.
干细胞因子 (SCF) 是一种二聚体分子,通过与受体酪氨酸激酶 c-Kit 结合并激活来发挥其生物学功能。c-Kit 的激活导致其自身磷酸化并启动信号转导。信号蛋白通过特定的相互作用域(例如 SH2 和 PTB)被募集到激活的 c-Kit 上,这些相互作用域特异性地结合 c-Kit 细胞内区域中磷酸化的酪氨酸残基。根据细胞类型的不同,c-Kit 信号的激活被发现介导细胞存活、迁移和增殖。c-Kit 信号的传导对于正常的造血、色素沉着、生育、肠道运动和神经系统的某些方面至关重要。在许多病理条件下,包括癌症和过敏,已经发现 c-Kit 的激酶活性失调。观察到 c-Kit 中的功能获得性突变可以促进肿瘤的形成和进展,这刺激了针对该受体的治疗剂的开发,例如临床上使用的抑制剂伊马替尼甲磺酸盐。此外,其他临床上使用的多选择性激酶抑制剂,例如索拉非尼和舒尼替尼,也将 c-Kit 纳入其作用靶点范围。此外,还观察到 c-Kit 的功能丧失性突变,并发现其导致一种称为斑驳病的疾病。本综述提供了有关 c-Kit 信号在正常和病理条件下的结构和功能方面的最新知识的摘要,以及抑制 c-Kit 功能的低分子量分子的开发进展。